Interleukin 2 signaling is required for CD4+ regulatory T cell function

被引:498
作者
Furtado, GC
de Lafaille, MAC
Kutchukhidze, N
Lafaille, JJ
机构
[1] NYU, Sch Med, Skirball Inst Biomol Med, Program Mol Pathognesis, New York, NY 10016 USA
[2] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
关键词
CD4(+) T lymphocytes; immune tolerance; encephalomyelitis; autoimmunity; hypersensitivity;
D O I
10.1084/jem.20020190
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mice deficient in interleukin (IL)-2 production or the IL-2 receptor α or β chains develop a lethal autoimmune syndrome. CD4+ regulatory T cells have been shown to prevent autoimmune diseases, allograft rejection, and to down-regulate antibody responses against foreign antigens. To assess the role of IL-2 in the generation and function of regulatory T cells, we transferred CD4+ T cells from mice genetically deficient in IL-2 or IL-2Rα (CD25) expression. A small number of splenic or thymic CD4+ T cells from IL-2 knockout mice can protect mice from spontaneous experimental autoimmune encephalomyelitis (EAE). In contrast, splenic or thymic CD4+ T cells from CD25 knockout donor mice conferred little or no protection. We conclude that T cells with regulatory potential can develop, undergo thymic selection, and migrate to the peripheral lymphoid organs in the absence of IL-2, and do not protect from disease by means of IL-2 secretion. However, IL-2 signaling in regulatory T cells is essential for their protective function. Altogether, our results favor a model whereby IL-2 induces regulatory T cell activity.
引用
收藏
页码:851 / 857
页数:7
相关论文
共 37 条
  • [1] CD25+ CD4+ T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10
    Annacker, O
    Pimenta-Araujo, R
    Burlen-Defranoux, O
    Barbosa, TC
    Cumano, A
    Bandeira, A
    [J]. JOURNAL OF IMMUNOLOGY, 2001, 166 (05) : 3008 - 3018
  • [2] An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation
    Asseman, C
    Mauze, S
    Leach, MW
    Coffman, RL
    Powrie, F
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1999, 190 (07) : 995 - 1003
  • [3] High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
    Atkins, MB
    Lotze, MT
    Dutcher, JP
    Fisher, RI
    Weiss, G
    Margolin, K
    Abrams, J
    Sznol, M
    Parkinson, D
    Hawkins, M
    Paradise, C
    Kunkel, L
    Rosenberg, SA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) : 2105 - 2116
  • [4] REGULATION OF INTERLEUKIN-2 (IL 2) RECEPTOR EXPRESSION - IL 2 AS AN INDUCING SIGNAL FOR THE EXPRESSION OF ITS OWN RECEPTOR ON A MURINE T-HELPER CELL-LINE
    BISMUTH, G
    MOREAU, JL
    SOMME, G
    DUPHOT, M
    DAUTRYVARSAT, A
    ROBB, RJ
    THEZE, J
    [J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 1985, 15 (07) : 723 - 727
  • [5] Bukowski RM, 1997, CANCER-AM CANCER SOC, V80, P1198, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO
  • [6] 2-H
  • [7] Phase II trial of systemic recombinant interleukin-2 in the treatment of refractory nasopharyngeal carcinoma
    Chi, KH
    Myers, JN
    Chow, KC
    Chan, WK
    Tsang, YW
    Chao, Y
    Yen, SH
    [J]. ONCOLOGY, 2001, 60 (02) : 110 - 115
  • [8] Hyper immunoglobulin E response in mice with monoclonal populations of B and T lymphocytes
    de Lafaille, MAC
    Muriglan, S
    Sunshine, MJ
    Lei, Y
    Kutchukhidze, N
    Furtado, GC
    Wensky, AK
    Olivares-Villagómez, D
    Lafaille, JJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 194 (09) : 1349 - 1359
  • [9] Furtado GD, 2001, IMMUNOL REV, V182, P122
  • [10] Inducible IL-2 production by dendritic cells revealed by global gene expression analysis
    Granucci, F
    Vizzardelli, C
    Pavelka, N
    Feau, S
    Persico, M
    Virzi, E
    Rescigno, M
    Moro, G
    Ricciardi-Castagnoli, P
    [J]. NATURE IMMUNOLOGY, 2001, 2 (09) : 882 - 888